Navigation Links
Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
Date:1/3/2008

ation clinical trial for patients with metastatic ovarian, peritoneal or fallopian tube cancers, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015 In response to recent ... and The US Postal Service to no longer ... ,select agents, by the CDC, Marken reaffirmed today ... sensitive shipments. Marken uses its flexible ... and certified personnel to ensure the safe and ...
(Date:8/26/2015)... Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... advanced testing solutions for the detection of foodborne pathogens, ... at the Sidoti & Company Emerging Growth Conference on ... held at the New York Marriott Marquis. ... available through the investor relations section of Roka Bioscience,s ...
(Date:8/26/2015)... Aug. 26, 2015 Intrexon Corporation (NYSE: ... the closing of its previously announced public offering of ... underwriters of their option to purchase an additional 731,707 ... of $41.00 per share.  The exercise of the underwriters, ... stock sold by Intrexon to 5,609,756 shares and increased ...
(Date:8/26/2015)... , August 26, 2015 ... biggest factors fueling the optimism in biotech,s forecast ... collaborations and life sciences advancements.  Active biotechnology & ... Pressure BioSciences, Inc. (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: ... SRPT ), Raptor Pharmaceutical Corp. (NASDAQ: RPTP ...
Breaking Biology Technology:Marken Ensures Safe Transportation Of Select Agents And Toxins 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
... Thermo Fisher,Scientific Inc. (NYSE: TMO ), the world ... the 2008 Merrill Lynch Global Pharmaceutical,Biotechnology & Medical Device ... York City. The company will present on Thursday, February ... president and chief executive officer of Thermo,Fisher Scientific, will ...
... BD (Becton,Dickinson and Company) (NYSE: BDX ) announced ... today, elected Basil L. Anderson,Marshall O. Larsen, Gary A. ... of Directors. The BD Board currently consists of 13 ... Edward J. Ludwig,Chairman, President and Chief Executive Officer., ...
... SANTA CRUZ, Calif., Jan. 29 Expanding ... career resources to post-graduate and,alumni candidates, Bio Career ... joined forces., On Jan. 28, Emory University, ... Bio Career Center family, rounding out an,already elite ...
Cached Biology Technology:Thermo Fisher Scientific to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2BD Announces Results of Shareholder Votes at Annual Meeting 2Online Career Site for Life Science Professionals Continues Growth 2
(Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... it survives on a diet of roundworm. But ... associate professor of biomedical engineering at the University of Tennessee, ... fighter. Zhang and his team have discovered that ... stimulating the immune system and killing tumors. The findings are ...
... NEW YORK, Dec. 4, 2012 A recent ABC News ... systems—to help ensure greater security in large childcare facilities. While ... stave off unwanted visitors and protect children from exiting the ... those who come in and out of the building. Slava ...
... of Seville (Spain) have developed a technique for estimating grape ... forward an index for identifying the ripeness of seeds without ... to decide the best moment for picking. The normal ... analysis. But this is a long and tedious task that ...
Cached Biology News:University of Tennessee researchers find fungus has cancer-fighting power 2Slava Volman Responds to Use of Biometrics for Security in Childcare Facilities 2A digital portrait for grapes indicates their ripeness 2
... (RNA polymers) are prepared ... of the enzyme, polynucleotide ... and the appropriate, ribonucleoside ... the exception of catalog ...
... Heavy duty stainless-steel shaker flask clips, ... high speeds. All clips are equipped ... (over 1L.) also include a bottom retainer ... prevent scratching of expensive glassware. Clips ...
RABBIT ANTI HUMAN ALPHA-2-ANTIPLASMIN...
... Bullseye Red Taq DNA Polymerase ... exhibits very high activity in primer extension ... contains a red dye which provides easy ... enzyme was added and allows confirmation of ...
Biology Products: